Data compiled by Redley Lamar · ChainSifter Intelligence
3Suppliers
5Customers
3Debt Items
1Related Chains
Source-Backed Evidence Depth
Sigyn Therapeutics, Inc. (SIGY) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
11Total relationships
1Distinct source URLs
7High confidence
0.791Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Sigyn Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
HGIT-HISTORIC-DECATUR-LP
HGIT-HISTORIC-DECATUR-LP
92%
On May 15, 2025, the Company entered into a lease termination agreement with HGIT Historic Decatur LP to terminate the Company’s San Diego, California office space.
INNOVATIVE-BIOTHERAPIES-INC
INNOVATIVE-BIOTHERAPIES-INC
90%
Our pre-clinical in vitro blood plasma studies we each performed under an agreement with Innovative BioTherapies, Inc. (IBT)
Reciprocal relationship from OGEN graph: we seek to enhance shareholder value by evaluating business development opportunities both within and complementary to our current business, as well as opport…
Sigyn Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
REIGN-RESOURCES-CORPORATION
REIGN-RESOURCES-CORPORATION
85%
and development costs are expensed as incurred. The Company incurred research and development expense of $ 29,681 and $ 46,004 , and $ 206,161 and $ 679,183 for the three and nine months ended Septem…
BRIO-CAPITAL-MASTER-FUND-LTD
BRIO-CAPITAL-MASTER-FUND-LTD
62%
rrants On June 5, 2025, as a means to induce further investment from established shareholders, the Company adjusted the conversion price of the Company’s outstanding warrants from $6.00 per share to …
CFI-CAPITAL-LLC
CFI-CAPITAL-LLC
62%
rrants On June 5, 2025, as a means to induce further investment from established shareholders, the Company adjusted the conversion price of the Company’s outstanding warrants from $6.00 per share to …
INNOVATIVE-BIOTHERAPIES-INC
INNOVATIVE-BIOTHERAPIES-INC
62%
o Series B Convertible Preferred Stock in accordance with their terms upon a listing of the Company’s common stock on a national securities exchange such as Nasdaq Capital Market. Extension of Notes …
OSHER-CAPITAL-PARTNERS-LLC
OSHER-CAPITAL-PARTNERS-LLC
62%
rrants On June 5, 2025, as a means to induce further investment from established shareholders, the Company adjusted the conversion price of the Company’s outstanding warrants from $6.00 per share to …
Sigyn Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
SIGY-DEBT-12529
Warrants outstanding: 559839
90%
xbrl warrant detail from xbrl 2024-12-31.
SIGY-DEBT
Debt stack $4.3M
90%
Market cache reports total debt of $4.3M.
SIGY-DEBT-12530
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2024-12-31.
Sigyn Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Sigyn Therapeutics, Inc..
Sigyn Therapeutics, Inc. Ownership
No ownership data on recordNo major institutional ownership relationships found in our database for Sigyn Therapeutics, Inc..
Sigyn Therapeutics, Inc. Extended Supply Chain Network
